Detalhe da pesquisa
1.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
N Engl J Med
; 377(24): 2349-2362, 2017 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29236639
2.
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Lancet Infect Dis
; 23(12): 1370-1382, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37579773
3.
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
Lancet Infect Dis
; 23(1): 103-116, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087588
4.
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Vaccine
; 40(2): 351-358, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34961633
5.
Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older.
Vaccine
; 40(12): 1872-1878, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164991
6.
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Vaccine
; 39(32): 4545-4554, 2021 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34215452
7.
Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data.
Infect Dis Ther
; 9(3): 625-639, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32681472
8.
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
Infect Dis Ther
; 9(3): 641-656, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700260
9.
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
Hum Vaccin
; 5(10): 696-704, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19855170
10.
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vaccine
; 37(12): 1710-1719, 2019 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770221
11.
Modeling excess zeroes in an integrated analysis of vaccine safety.
Hum Vaccin Immunother
; 14(6): 1530-1533, 2018 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29393713
12.
Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Vaccine
; 36(28): 4004-4013, 2018 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29861182
13.
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.
Papillomavirus Res
; 3: 105-115, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28720442
14.
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.
Pediatr Infect Dis J
; 34(6): 627-34, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25831420
15.
Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.
Hum Vaccin Immunother
; 11(6): 1306-12, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26086587
16.
Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.
Pediatrics
; 136(3): e563-72, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26240207
17.
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Hum Vaccin Immunother
; 11(6): 1313-22, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25912208
18.
Immunogenicity and Safety of a 9-Valent HPV Vaccine.
Pediatrics
; 136(1): e28-39, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26101366
19.
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
BMJ
; 341: c3493, 2010 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20647284
20.
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Cancer Prev Res (Phila)
; 2(10): 868-78, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19789295